Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Publications: Western Australian Centre for Thrombosis and Haemostasis (WACTH)

Export as [feed] RSS
Group by: Item Type | Year
Number of items at this level: 14.

Journal Article

Casari, I., Manfredi, M., Metharom, P. and Falasca, M. (2021) Dissecting lipid metabolism alterations in SARS-CoV-2. Progress in Lipid Research, 82 . Art. 101092.

Elaskalani, O., Domenichini, A., Abdol Razak, N., E. Dye, D., Falasca, M. and Metharom, P. (2020) Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT Pathway in pancreatic cancer cells. Cancers, 12 (1). Art. 250.

Favaloro, E., Gilmore, G., Arunachalam, S., Mohammed, S. and Baker, R. (2019) Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research, 180 . pp. 10-19.

Favaloro, E.J., Gilmore, G., Bonar, R., Dean, E., Arunachalam, S., Mohammed, S. and Baker, R. (2020) Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. Clinical Chemistry and Laboratory Medicine, 58 (8).

Favaloro, E.J., Gilmore, G., Bonar, R., Dean, E., Arunachalam, S., Mohammed, S. and Baker, R. (2020) Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia . Early View.

Fogarty, H., Townsend, L., Morrin, H., Ahmad, A., Comerford, C., Karampini, E., Englert, H., Byrne, M., Bergin, C., O’Sullivan, J.M., Martin‐Loeches, I., Nadarajan, P., Bannan, C., Mallon, P.W., Curley, G.F., Preston, R.J.S., Rehill, A.M., McGonagle, D., Ni Cheallaigh, C., Baker, R.I., Renné, T., Ward, S.E., O’Donnell, J.S., O’Connell, N., Ryan, K., Kenny, D. and Fazavana, J. (2021) Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Journal of Thrombosis and Haemostasis .

Ho, K.M., Rao, S., Honeybul, S., Zellweger, R., Wibrow, B., Lipman, J., Holley, A., Kop, A., Geelhoed, E., Corcoran, T., Misur, P., Edibam, C., Baker, R.I., Chamberlain, J., Forsdyke, C. and Rogers, F.B. (2019) A multicenter Trial of Vena Cava filters in severely injured patients. New England Journal of Medicine, 381 (4). pp. 328-337.

Mackie, I., Mancini, I., Muia, J., Kremer Hovinga, J., Nair, S., Machin, S. and Baker, R. (2020) International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. International Journal of Laboratory Hematology . Early View.

Matasar, M.J., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M-C, Baker, R., Bondarenko, I., Zhang, Q., Feng, J., Geissler, K., Lazaroiu, M., Saydam, G., Szomor, Á., Bouabdallah, K., Galiulin, R., Uchida, T., Soler, L.M., Cao, A., Hiemeyer, F., Mehra, A., Childs, B.H., Shi, Y. and Zinzani, P.L. (2021) Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). Cancer Research, 81 (13 Suppl.). CT001.

Oh, J., Oh, D., Lee, S.J., Kim, J.H., Kim, N.K., Chong, S.Y., Huh, J.Y. and Baker, R.I. (2019) Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Research, 54 (3). pp. 218-228.

Tian, J., Adams, M.J.ORCID: 0000-0002-7743-4515, Tay, J.W.T., James, I., Powell, S., Hughes, Q.W., Gilmore, G., Baker, R.I. and Tiao, J.Y-H. (2021) Estradiol-Responsive miR-365a-3p Interacts with Tissue Factor 3′UTR to Modulate Tissue Factor-Initiated Thrombin Generation. Thrombosis and Haemostasis .

Tiao, J., Powell, S., Gilmore, G., Veedu, R., Wilton, S. and Baker, R. (2020) Splice inducing Antisense Oligonucleotides as a potential gene correction therapy for haemophilia A. Haemophilia, 26 (S4). pp. 21-22.

Ward, S.E., Fogarty, H., Karampini, E., Lavin, M., Schneppenheim, S., Dittmer, R., Morrin, H., Glavey, S., Ni Cheallaigh, C., Bergin, C., Martin‐Loeches, I., Mallon, P.W., Curley, G.F., Baker, R.I., Budde, U., O’Sullivan, J.M., O’Donnell, J.S., O’Connell, N., Byrne, M., Townsend, L., McEvoy, N.L., Clarke, J., Boylan, M., Alalqam, R., Worrall, A.P., Kelly, C., de Barra, E., Preston, R. and Kenny, D. (2021) ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19. Journal of Thrombosis and Haemostasis . Early View.

Zinzani, P.L., Capra, M., Özcan, M., Lv, F., Li, W., Yañez, E., Sapunarova, K., Lin, T., Jin, J., Jurczak, W., Hamed, A., Wang, M.C., Baker, R., Bondarenko, I., Zhang, Q., Feng, J., Geissler, K., Lazaroiu, M., Saydam, G., Szomor, Á., Bouabdallah, K., Galiulin, R., Uchida, T., Mongay Soler, L., Cao, A., Hiemeyer, F., Mehra, A., Childs, B.H., Shi, Y. and Matasar, M.J. (2021) CHRONOS‐3: Randomized phase III study of copanlisib plus rituximab/placebo in relapsed indolent Non-Hodgkin Lymphoma (INHL). Hematological Oncology, 39 (S2).

This list was generated on Wed Sep 22 14:48:17 2021 UTC.